Nerandomilast (Jascayd) Approved for Idiopathic and Progressive Pulmonary Fibrosis
Nerandomilast has received approval from the MHRA for the treatment of adult patients with idiopathic and progressive pulmonary fibrosis.
Asset / Drug
Drug and asset intelligence for Nerandomilast with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.